Dermatophytic onychomycosis: Key market research findings
- Increased focus on combination therapies
- Growing investments in research activities
Technavio has released a new market research report on the global dermatophytic onychomycosis market, which is expected to grow at a CAGR of 7% by 2020. Walking barefoot in damp public places, immunosuppressive conditions such as HIV, excessive sweating due to vigorous physical activity, family history, circulation problems, and an increase in the prevalence of diabetes has increased the prevalence of dermatophytic onychomycosis. The Americas dominate the dermatophytic onychomycosis market, owing to the well-developed healthcare system coupled with better economic conditions in the region.
The new industry research report from Technavio discusses in detail the key drivers and trends responsible for the growth of this market and its sub-segments
“Of late, the market is witnessing increased adoption of combination therapies to improve the cure rate of dermatophytic onychomycosis. The most commonly used combination therapy of amorolfine nail lacquer and oral terbinafine has improved clinical efficiency and is more cost-effective. Physians are also using the combination of surgery and systemic and topical therapies. Now-a-days, non-pharmacological approaches such as laser or mechanical treatment are also used in combination with topical and systemic therapy,” says Imran Mushtaq, Industry Manager, Healthcare & Lifesciences, Technavio Research
The market provides huge growth opportunities for vendors due to the growing demand for effective pharmacological therapeutics to treat nail fungus. Currently, the market is faced with significant unmet needs due to the low efficacy of drugs, prolonged treatment times, side effects associated with oral therapies, and the high cost of treatment. Vendors such as Anacor Pharmaceuticals, Novartis, and Pfizer, are making huge investments in research activities to develop oral and topical agents that effectively treat the condition.
The leading vendors in the global dermatophytic onychomycosis market are Anacor Pharmaceuticals, Galderma, Janssen Pharmaceutical, Novartis, and Valeant Pharmaceuticals. The market is highly competitive, with the presence of numerous small and large vendors that operate at a local or global scale. The market has huge growth potential which has increased the entry of new players.
A more detailed analysis is available in the Technavio report, Global Dermatophytic Onychomycosis Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
